C.E.S. TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
23-09-2020
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
CONJUGATED ESTROGENS
Beschikbaar vanaf:
BAUSCH HEALTH, CANADA INC.
ATC-code:
G03CA57
INN (Algemene Internationale Benaming):
CONJUGATED ESTROGENS
Dosering:
0.625MG
farmaceutische vorm:
TABLET
Samenstelling:
CONJUGATED ESTROGENS 0.625MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100/1000
Prescription-type:
Prescription
Therapeutisch gebied:
ESTROGENS
Product samenvatting:
Active ingredient group (AIG) number: 0106442006; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2020-09-23
Productkenmerken
PRODUCT MONOGRAPH
PR
C.E.S.
Conjugated Estrogens Tablets, CSD
0.625 mg
ESTROGEN
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION:
2150 St-Elzear Blvd. West
September 23, 2020
Laval, Quebec
H7L 4A8
Control No.: 242944
_Pr_
_C.E.S._
_®_
_ Product Monograph Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................20
SPECIAL HANDLING INSTRUCTIONS
.......................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
CLINICAL TRIALS
..........................................................................................................24
DETAIL
Lees het volledige document
